Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

oking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.


Contact:

Investors                               Media
Eugenia Shen                            Susan Berg
BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
(415) 506-6570                          (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... DIEGO, Dec. 12, 2011  Receptos Inc. announced today the ... Ltd. (Osaka, Japan) for the research and development ... coupled receptor (GPCR) target. Under the terms of ... platform to produce high resolution protein crystal structures ...
... Dec. 12, 2011  Stemline Therapeutics, Inc. today announced that ... scheduled to present at the Oppenheimer 22nd Annual Healthcare ... ET at the Waldorf Astoria Hotel in New York ... Stemline Therapeutics, Inc. is a clinical stage ...
... 12, 2011 Silence Therapeutics plc ... interference ( RNAi ) therapeutics company, announces that the United ... of four key RNAi patents that form part of the ... by an anonymous third party during 2010, the USPTO has ...
Cached Biology Technology:Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 3Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 2Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 3Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 4
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2012 - Every process in a cell is affected ... the human body and their relationship to diseases is ... therapies. The Ontario Genomics Institute (OGI) is providing $100,000 ... University of Toronto (U of T),s Mammalian Membrane Two-Hybrid ...
... Predicting how atherosclerosis, osteoporosis or cancer will progress ... difficult. In a new study, researchers took another ... able to predict from a blood sample the ... diseasesa specific person would produce. This ...
... for medical and biological research, but are difficult to study ... from adults may provide a path to study stem cells ... JoVE ( Journal of Visualized Experiments ), details ... cells in the peripheral blood. The technique has been ...
Cached Biology News:Ontario Genomics Institute invests in validation of a novel protein interaction technology at U of T 2Researchers use blood testing to predict level of enzymes that facilitate disease progression 2Novel technique to produce stem cells from peripheral blood 2
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... F-12 was developed for culturing hybrid cells ... modification consists of doubling the amino acids ... salt concentrations have been altered as well. ... per liter, which may render it unsuitable ...
... Alsevers solution is an isotonic, balanced salt ... preservative, which permits the storage of whole blood ... usage, an equal volume of blood is collected ... but thoroughly, mixed. The solution is placed in ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: